Randialic acid B

Research use only, not for human use.

Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury.

Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury.

Randialic acid B (0.1-3 μM; for 5 min) selectively inhibits reactive oxygen species production, elastase release, and CD11b expression in human neutrophils activated by FPR1. Randialic acid B inhibits the binding of N-formyl peptide to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells, indicating FPR1 antagonism. Randialic acid B acts competitively for its binding to the FPR1 receptor. The FPR1-downstream signaling such as Ca2+ mobilisation and activation of Akt and MAPKs is also competitively inhibited. Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury.

Randialic acid B (10 mg/kg; i.v.; every other day; for 5 days) significantly reduces Imiquimod-induced psoriasis-like symptom, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss. Animal Model:BALB/c white female mice (20 g weight; 7-week-old) treated with Imiquimod Dosage:10 mg/kg Administration:i.v.; every other day; for 5 days Result:Significantly reduced Imiquimod-induced psoriasis-like symptoms.

——

Others

Other Targets

——

——

——

14021-14-8

454.7

C30H46O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (219.93 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years